Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Portfolio Pulse from
Johnson & Johnson has decided not to exercise its option to license Genmab's HexaBody-CD38, leading Genmab to halt further clinical development of the drug despite promising initial data.
March 10, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Genmab announced that Johnson & Johnson will not license HexaBody-CD38, leading Genmab to stop its development. This decision may impact Genmab's stock negatively due to halted progress on a promising drug.
The decision by J&J not to license HexaBody-CD38 is significant for Genmab as it halts the development of a promising drug. This could lead to a negative short-term impact on Genmab's stock due to the loss of potential revenue and market opportunity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Johnson & Johnson decided not to license Genmab's HexaBody-CD38, indicating a strategic choice to not pursue this particular drug, which may have a neutral impact on J&J's stock.
J&J's decision not to license HexaBody-CD38 suggests a strategic choice rather than a negative reflection on the company. The impact on J&J's stock is likely neutral as the decision aligns with portfolio management rather than a failure.
CONFIDENCE 85
IMPORTANCE 50
RELEVANCE 50